Disclosed herein is a strategy for the engineering of recombinant vaccines against major human and animal pathogens of the paramyxovirus family. Also disclosed are recombinant virus able to replicate without being pathogenic. Also disclosed is a method of immunizing a subject against infection with a that involves administering to the subject a recombinant vaccine disclosed herein.

The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.

The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.

The present invention relates to liquid vaccine composition comprising a live virus and a natural deep-eutectic solvent (NADES) as the carrier. The carrier additionally comprises an additive selected from methionine and (hydroxy) ectoine. The additive is able to reduce the loss of virus titre over time, upon storage in a NADES-based liquid vaccine composition having up to 50% w/w of water. Such compositions are less viscous which is favourable for the manufacture of the carrier, and the formulation and use of the liquid vaccine.

The present invention relates to liquid vaccine composition comprising a live virus and a natural deep-eutectic solvent (NADES) as the carrier. The carrier additionally comprises an additive selected from methionine and (hydroxy) ectoine. The additive is able to reduce the loss of virus titre over time, upon storage in a NADES-based liquid vaccine composition having up to 50% w/w of water. Such compositions are less viscous which is favourable for the manufacture of the carrier, and the formulation and use of the liquid vaccine.

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

The present invention relates to compositions and methods for treating and/or preventing Canine Distemper Virus (CDV) in mammals susceptible to CDV.

The present invention relates to compositions and methods for treating and/or preventing Canine Distemper Virus (CDV) in mammals susceptible to CDV.

Embodiments of the present disclosure provide novel compositions and methods for making and using thermostable polynucleotide-containing formulations. In certain embodiments, compositions and methods are disclosed for creating thermostable polynucleotides and/or thermostable polynucleotides encoding at least one therapeutic agent for use in therapies for the treatment of health conditions in a subject. In some embodiments, compositions and methods are disclosed for creating thermostable polynucleotides for use in therapeutics, vaccines, and targeted gene therapies. In other embodiments, compositions and methods are disclosed for creating thermostable polynucleotides capable of being coated or encased for prolonged storage and/or timed-delivery.